Top

World Journal of Urology

Published in:

Open Access 01-11-2020 | Prostatitis | Original Article

Chronic inflammation promotes proliferation in the prostatic stroma in rats with experimental autoimmune prostatitis: study for a novel method of inducing benign prostatic hyperplasia in a rat model

Authors: Mengyang Zhang, Changcheng Luo, Kai Cui, Tao Xiong, Zhong Chen

Published in: World Journal of Urology | Issue 11/2020

Abstract

Objective

Inflammation plays an important role in the development of benign prostatic hyperplasia (BPH). The aim of the present study was to reference the study of the pathological changes in the prostate gland of rats with experimental autoimmune prostatitis (EAP), for the development of experimental models of BPH.

Methods

Experimental autoimmune prostatitis was induced in rats by the intradermal injection of rat prostate antigen with immunoadjuvants. In case of the positive BPH group, BPH was induced by the subcutaneous injection of testosterone propionate. At the end of the 45-day model period, prostate weights were measured, and the histopathological analysis of the prostate glands was performed. The levels of cytokines, TGF-β1/RhoA/ROCK signals, and the oxidative stress status were also examined.

Results

Rats from the EAP group had a higher histological score than those from the control group. Compared to the samples from rats in the hormone-induced group, those from the EAP group showed a more pronounced increase in the size of the stromal compartment; this was characterized by the formation of reactive stroma and the deposition of a greater amount of extracellular matrix (ECM). Significant increases in the numbers of CD3-positive cells and CD68-positive cells, as well as a significant upregulation in the cytokine levels, and an increase in the TGF-β1 levels and activation of RhoA/ROCK signaling, were observed in the samples from rats in the EAP group.

Conclusion

Chronic inflammation can induce BPH in rats via EAP model method. When performing drug experiments on the stroma compartments of BPH, the use of the EAP model is a recommendation of the authors based on this study.

Ekman P (1989) BPH epidemiology and risk factors. Prostate Suppl 2:23–31. https://doi.org/10.1002/pros.2990150505CrossRef

Roehrborn CG (2008) Pathology of benign prostatic hyperplasia. Int J Impot Res 20(Suppl 3):S11–18. https://doi.org/10.1038/ijir.2008.55CrossRef

Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F (2013) The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 112(4):432–441. https://doi.org/10.1111/bju.12118CrossRef

Kohnen PW, Drach GW (1979) Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 121(6):755–760. https://doi.org/10.1016/s0022-5347(17)56980-3CrossRef

Wu ZL, Yuan Y, Geng H, Xia SJ (2012) Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue. Asian J Androl 14(2):316–319. https://doi.org/10.1038/aja.2011.154CrossRef

Robert G, Descazeaud A, Nicolaiew N, Terry S, Sirab N, Vacherot F, Maille P, Allory Y, de la Taille A (2009) Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 69(16):1774–1780. https://doi.org/10.1002/pros.21027CrossRef

Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM, Motiwala HG, Laniado ME (2007) Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 100(2):327–331. https://doi.org/10.1111/j.1464-410X.2007.06910.xCrossRef

Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B (2013) Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol 23(1):5–10. https://doi.org/10.1097/MOU.0b013e32835abd4aCrossRef

Sun F, Baez-Diaz C, Sanchez-Margallo FM (2017) Canine prostate models in preclinical studies of minimally invasive interventions: part II, benign prostatic hyperplasia models. Transl Androl Urol 6(3):547–555. https://doi.org/10.21037/tau.2017.03.62CrossRef

10.

Park BK, Kim CW, Kwon JE, Negi M, Koo YT, Lee SH, Baek DH, Noh YH, Kang SC (2019) Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia. Pharm Biol 57(1):90–98. https://doi.org/10.1080/13880209.2018.1564929CrossRef

11.

Konkol Y, Vuorikoski H, Streng T, Tuomela J, Bernoulli J (2019) Characterization a model of prostatic diseases and obstructive voiding induced by sex hormone imbalance in the Wistar and Noble rats. Transl Androl Urol 8(Suppl 1):S45–S57. https://doi.org/10.21037/tau.2019.02.03CrossRef

12.

Miao L, Jiao C, Shao R, Qi Y, Fan G, Li X, Wang Y, Zhu Y, Zhang J, Gao X (2019) Bakuchiol suppresses oestrogen/testosterone-induced Benign Prostatic Hyperplasia development through up-regulation of epithelial estrogen receptor beta and down-regulation of stromal aromatase. Toxicol Appl Pharmacol 381:114637. https://doi.org/10.1016/j.taap.2019.114637CrossRef

13.

Jeon WY, Kim OS, Seo CS, Jin SE, Kim JA, Shin HK, Kim YU, Lee MY (2017) Inhibitory effects of Ponciri Fructus on testosterone-induced benign prostatic hyperplasia in rats. BMC Complement Altern Med 17(1):384. https://doi.org/10.1186/s12906-017-1877-yCrossRef

14.

Huhtaniemi I (2014) Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. Asian J Androl 16(2):192–202. https://doi.org/10.4103/1008-682X.122336CrossRef

15.

Zhou XH, Li LD, Wu LM, Han L, Liu ZD, Yang JX, Lv YW, You CL, Zhou ZH (2007) Increased inflammatory factors activity in model rats with experimental autoimmune prostatitis. Arch Androl 53(2):49–52. https://doi.org/10.1080/01485010600908397CrossRef

16.

Cui K, Luan Y, Tang Z, Rao K, Wang T, Chen Z, Wang S, Liu J, Wang D (2017) Involvement of DDAH/ADMA/NOS/cGMP and COX-2/PTGIS/cAMP pathways in human tissue Kallikrein 1 protecting erectile function in aged rats. PLoS ONE 12(1):e0170427. https://doi.org/10.1371/journal.pone.0170427CrossRef

17.

Scolnik MD, Servadio C, Abramovici A (1994) Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains. J Androl 15(4):287–297

18.

Golomb E, Rosenzweig N, Eilam R, Abramovici A (2000) Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 21(1):58–64

19.

Strand DW, Costa DN, Francis F, Ricke WA, Roehrborn CG (2017) Targeting phenotypic heterogeneity in benign prostatic hyperplasia. Differentiation 96:49–61. https://doi.org/10.1016/j.diff.2017.07.005CrossRef

20.

Nicholson TM, Ricke WA (2011) Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82(4–5):184–199. https://doi.org/10.1016/j.diff.2011.04.006CrossRef

21.

Davies P, Eaton CL (1991) Regulation of prostate growth. J Endocrinol 131(1):5–17. https://doi.org/10.1677/joe.0.1310005CrossRef

22.

Morales A (2002) Androgen replacement therapy and prostate safety. Eur Urol 41(2):113–120. https://doi.org/10.1016/s0302-2838(01)00039-2CrossRef

23.

De Nunzio C, Presicce F, Tubaro A (2016) Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol 13(10):613–626. https://doi.org/10.1038/nrurol.2016.168CrossRef

24.

Zhou J, Lei Y, Chen J, Zhou X (2018) Potential ameliorative effects of epigallocatechin 3 gallate against testosterone-induced benign prostatic hyperplasia and fibrosis in rats. Int Immunopharmacol 64:162–169. https://doi.org/10.1016/j.intimp.2018.08.038CrossRef

25.

Jena AK, Vasisht K, Sharma N, Kaur R, Dhingra MS, Karan M (2016) Amelioration of testosterone induced benign prostatic hyperplasia by Prunus species. J Ethnopharmacol 190:33–45. https://doi.org/10.1016/j.jep.2016.05.052CrossRef

26.

Ishola IO, Tijani HK, Dosumu OO, Anunobi CC, Oshodi TO (2017) Atorvastatin attenuates testosterone-induced benign prostatic hyperplasia in rats: role of peroxisome proliferator-activated receptor-gamma and cyclo-oxygenase-2. Fundam Clin Pharmacol 31(6):652–662. https://doi.org/10.1111/fcp.12301CrossRef

27.

Yang X, Yuan L, Xiong C, Yin C, Ruan J (2014) Abacopteris penangiana exerts testosterone-induced benign prostatic hyperplasia protective effect through regulating inflammatory responses, reducing oxidative stress and anti-proliferative. J Ethnopharmacol 157:105–113. https://doi.org/10.1016/j.jep.2014.09.025CrossRef

28.

Lee G, Shin J, Choi H, Jo A, Pan S, Bae D, Lee Y, Choi C (2017) Cynanchum wilfordii ameliorates testosterone-induced benign prostatic hyperplasia by regulating 5α-reductase and androgen receptor activities in a rat model. Nutrients. https://doi.org/10.3390/nu9101070CrossRef

29.

Franiel T, Ludemann L, Rudolph B, Rehbein H, Stephan C, Taupitz M, Beyersdorff D (2009) Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters. Radiology 252(1):101–108. https://doi.org/10.1148/radiol.2521081400CrossRef

30.

Shapiro E, Becich MJ, Hartanto V, Lepor H (1992) The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 147(5):1293–1297. https://doi.org/10.1016/s0022-5347(17)37546-8CrossRef

31.

Bushman WA, Jerde TJ (2016) The role of prostate inflammation and fibrosis in lower urinary tract symptoms. Am J Physiol Renal Physiol 311(4):F817–F821. https://doi.org/10.1152/ajprenal.00602.2015CrossRef

32.

Sampson N, Berger P, Zenzmaier C (2012) Therapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic disease. Oxid Med Cell Longev 2012:458276. https://doi.org/10.1155/2012/458276CrossRef

33.

Amano M, Nakayama M, Kaibuchi K (2010) Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken) 67(9):545–554. https://doi.org/10.1002/cm.20472CrossRef

34.

Kardassis D, Murphy C, Fotsis T, Moustakas A, Stournaras C (2009) Control of transforming growth factor beta signal transduction by small GTPases. FEBS J 276(11):2947–2965. https://doi.org/10.1111/j.1742-4658.2009.07031.xCrossRef

35.

Hou Y, DeVoss J, Dao V, Kwek S, Simko JP, McNeel DG, Anderson MS, Fong L (2009) An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. J Clin Invest 119(7):2031–2041. https://doi.org/10.1172/JCI38332CrossRef

36.

Motrich RD, Maccioni M, Molina R, Tissera A, Olmedo J, Riera CM, Rivero VE (2005) Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin Immunol 116(2):149–157. https://doi.org/10.1016/j.clim.2005.03.011CrossRef

37.

Motrich RD, Maccioni M, Ponce AA, Gatti GA, Oberti JP, Rivero VE (2006) Pathogenic consequences in semen quality of an autoimmune response against the prostate gland: from animal models to human disease. J Immunol 177(2):957–967. https://doi.org/10.4049/jimmunol.177.2.957CrossRef

38.

Breser ML, Motrich RD, Sanchez LR, Mackern-Oberti JP, Rivero VE (2013) Expression of CXCR3 on specific T cells is essential for homing to the prostate gland in an experimental model of chronic prostatitis/chronic pelvic pain syndrome. J Immunol 190(7):3121–3133. https://doi.org/10.4049/jimmunol.1202482CrossRef

39.

Maccioni M, Rivero VE, Riera CM (1998) Prostatein (or rat prostatic steroid binding protein) is a major autoantigen in experimental autoimmune prostatitis. Clin Exp Immunol 112(2):159–165. https://doi.org/10.1046/j.1365-2249.1998.00588.xCrossRef

40.

Depiante-Depaoli M, Pacheco-Rupil B, Britos S, Casas A (1984) Experimental autoimmune damage to rat male accessory glands I Transfer of autoimmune response by spleen cells. Am J Reprod Immunol 5(1):9–14. https://doi.org/10.1111/j.1600-0897.1984.tb00280.xCrossRef

41.

Fibbi B, Penna G, Morelli A, Adorini L, Maggi M (2010) Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 33(3):475–488. https://doi.org/10.1111/j.1365-2605.2009.00972.xCrossRef

42.

Minciullo PL, Inferrera A, Navarra M, Calapai G, Magno C, Gangemi S (2015) Oxidative stress in benign prostatic hyperplasia: a systematic review. Urol Int 94(3):249–254. https://doi.org/10.1159/000366210CrossRef

43.

Chang WH, Tsai YS, Wang JY, Chen HL, Yang WH, Lee CC (2019) Sex hormones and oxidative stress mediated phthalate-induced effects in prostatic enlargement. Environ Int 126:184–192. https://doi.org/10.1016/j.envint.2019.02.006CrossRef

44.

Ellem SJ, Risbridger GP (2009) The dual, opposing roles of estrogen in the prostate. Ann NY Acad Sci 1155:174–186. https://doi.org/10.1111/j.1749-6632.2009.04360.xCrossRef

45.

Wu X, Gu Y, Li L (2017) The anti-hyperplasia, anti-oxidative and anti-inflammatory properties of Qing Ye Dan and swertiamarin in testosterone-induced benign prostatic hyperplasia in rats. Toxicol Lett 265:9–16. https://doi.org/10.1016/j.toxlet.2016.11.011CrossRef

46.

Vignozzi L, Gacci M, Maggi M (2016) Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 13(2):108–119. https://doi.org/10.1038/nrurol.2015.301CrossRef

Title: Chronic inflammation promotes proliferation in the prostatic stroma in rats with experimental autoimmune prostatitis: study for a novel method of inducing benign prostatic hyperplasia in a rat model
Authors: Mengyang Zhang
Changcheng Luo
Kai Cui
Tao Xiong
Zhong Chen
Publication date: 01-11-2020
Publisher: Springer Berlin Heidelberg
Keywords: Prostatitis
Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy
Testosterone
Published in: World Journal of Urology / Issue 11/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-020-03090-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Chronic inflammation promotes proliferation in the prostatic stroma in rats with experimental autoimmune prostatitis: study for a novel method of inducing benign prostatic hyperplasia in a rat model

Abstract

Objective

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2020

The impact of extended pelvic lymph node dissection on the risk of hospital readmission within 180 days after robot assisted radical prostatectomy

The fate of urological systematic reviews registered in PROSPERO

Higher expression of phosphodiesterase type 5 in the anterior fibromuscular stroma of the human prostate

Infectious complications of prostate biopsy: winning battles but not war

Current perspectives on urolithiasis management in China

Candida urinary tract infections in adults